Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors

Eva-Lotta Allan’s excellent track record of corporate, business development and operational experience strengthens industry-leading Board and Executive Leadership team Maxion’s lead KnotBody® programme is progressing rapidly towards preclinical development with a first-in-class and…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.